linjc16/ctgov huggingface dataset:
Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy

Study Overview
=================
Brief Summary
-----------------
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, also known as statins, played an important role in lipid-lowering therapy and reduction of cardiovascular risks. However, it has been observed that the response to statin therapy varies from patient to patient, and gene polymorphism could have contributed to the variation.

Detailed Description
-----------------
Hyperlipidemic patients are retrospectively screened from 2006/1/1 to 2006/12/31. The patient is included if he or she had been receiving atorvastatin or rosuvastatin for at least 3 months and did not receive other lipid-lowering medications 4 weeks before starting atorvastatin or rosuvastatin. Genomic DNA was collected from the blood sample of each patient using genomic DNA purification kit. The single nucleotide polymorphisms (SNPs) were determined afterward. The correlation between response of statin therapy, defined as changes in lipid profiles including triglyceride, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol, and SNPs examined.

Official Title
-----------------
Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy

Conditions
-----------------
Statins, HMG-CoA, Single Nucleotide Polymorphism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 21-80. conforms with the criteria of National Cholesterol Education Program Adult Treatment Panel III for medication therapy. have received atorvastatin or rosuvastatin regularly for 12 weeks or longer. available lipid profiles such triglyceride, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol 12-24 weeks after staring statin therapy. Exclusion Criteria: had been using lipid-lowering medications including statins 4 weeks before starting atorvastatin or rosuvastatin. received other lipid-lowering medications, erythromycin, immunosuppressant or azole antifungals concomitantly. pregnant, breast-feeding, or able to become pregnant. have a history of alcohol or substance abuse. liver cirrhosis or ALT exceeds the upper limit of normal range. untreated hypothyroidism. patients with malignant tumor who have received chemotherapy or radiotherapy. known allergy to atorvastatin, rosuvastatin or other statins. unwilling to provide written informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Single Nucleotide Polymorphism, statins, hyperlipidemia
Comparison of 2-Dimensional and 3-Dimensional Laparoscopic Visions

Study Overview
=================
Brief Summary
-----------------
This study tests the hypothesis that use of the 3-D laparoscopic vision system (Viking Systems, La Jolla, CA) can significantly improve technical ability on a complex laparoscopic tasks in an experimental model.

Detailed Description
-----------------
7 tasks on a 3-D laparoscopic instrument fitted to the trainer box and subjective criteria (4 point lickert scale) were evaluated for this study. Totally twenty-four participants (8 experienced, 8 minimal experienced and 8 novices) were evaluated for different 10 tasks (touch the marked circle, pass the two circle with needle, pick-beads and place, grape the suture, move the needle from one instrument to another instrument, pick-and-place, cutting, three different suturing) in term of total task time and error number. Statistical Package Program was used to perform statistical analyses. The data were presented as arithmetic means and standard deviations were calculated in each group. A P value of <0.05 was considered to be statistically significant.

Official Title
-----------------
Comparison of 2-Dimensional and New Generation 3-Dimensional Laparoscopic Visions In An Experimental Model

Conditions
-----------------
Diagnostic Self Evaluation

Intervention / Treatment
-----------------
* Procedure: Laparoscopic surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: medical doctors Exclusion Criteria: disabled person (about arms or vision problems)

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Gynecologist<br>Gynecologist can use laparoscopic surgery. | Procedure: Laparoscopic surgery<br>* Two methods will be compare<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In order to test whether the 3-D laparoscopy vision system is superior or not than the 2-D laparoscopic vision system. | We want to test the 3-D laparoscopic vision system (Viking Systems, La Jolla, CA) can significantly improve technical ability on a complex laparoscopic tasks in an experimental model. 7 tasks on a 3-D laparoscopic instrument fitted to the trainer box and subjective criteria (4 point lickert scale) were evaluated for this study. Totally twenty-four participants (8 experienced, 8 minimal experienced and 8 novices) were evaluated for different 10 tasks in term of total task time and error number. | 15 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
laparoscopy, accuracy, duration
Effect of Fiber Supplementation in Children With Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
High fiber foods are recommended as a preferential source of carbohydrate by the Nutrition Study Group of the European Association for the Study of Diabetes. Dietary fibers may delay glucose absorption and reduce postprandial glycemic excursion. They also appear to have a beneficial effect on cholesterol levels. It has been shown, in few short term adult studies, that high fiber foods reduce postprandial blood glucose levels. The American Diabetes Association feels that there is little evidence confirming the positive effect of high fiber foods on blood glucose control. It is not clear whether a high fiber diet can improve glycemic control and/or reduce the risk of hypoglycemic events. Our hypothesis is that children with type 1 diabetes will benefit from having added fibers in their diet. The investigators plan to study blood glucose values using a continuous blood glucose monitor before and after dietary fibers are introduced. This will help us determine whether a diet rich in fiber should be recommended in all children with type 1 diabetes mellitus

Official Title
-----------------
Effects of Fiber Supplementation on Glycemic Excursions and Incidence of Hypoglycemia in Children With Type 1 Diabetes

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Dietary Supplement: soluble fiber in the form of benefiber


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The inclusion criteria are: Diagnosis of type I diabetes for at least two years prior to enrollment, the ability tolerate wearing the continuous blood glucose monitoring device for a total of 6 days, and the ability to follow a prescribed meal plan. Exclusion Criteria: The exclusion criteria are: Medical conditions that could potentially affect the absorption of nutrients such as celiac disease of inflammatory bowel disease and the use of any fiber supplements at home.

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of hypoglycemia after fiber supplementation |  | continuous glucose monitoring over 72 hours |
Study on Blood Glucose Variations in Tumor Patients Before and After Total Parenteral Nutrition

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the relationship among TPN, tumor and blood glucose.

Detailed Description
-----------------
Select the tumor patients in abdominal department after surgery with TPN. Monitor the blood glucose variation after TPN.

Official Title
-----------------
Phase 1: Select Tumor Patients to be Observed Phase 2: Observe the Blood Glucose Values During TPN Phase 3: Sort Data

Conditions
-----------------
Cancer, Surgery, Nutrition Related Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1.tumor patients,2.use TPN after surgery Exclusion Criteria: without using TPN
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tumor patients, TPN, surgery<br>This work involved prospective study of surgical patients receiving TPN during the calendar year of 2013 at Cancer Hospital. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycemic Variations during TPN | Observe the blood glucose variation in tumor patients after surgery. According to the TPN infusion time, the blood glucose values are divided into three parts: pre TPN, within 24h and after 24h. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TPN, abdominal surgery, blood glucose
Oxygen Consumption After Acute Whole Body Vibration Session

Study Overview
=================
Brief Summary
-----------------
Noninvasive assessment of VO2 during a single session of whole body vibration and changes in blood flow caused by the acute activity.

Detailed Description
-----------------
A single whole body vibration session into two groups, a young adults groups and elderly group, booth healthy, will be held with concomitant collection of VO2 consumed during the session, by MetaMax cortex. Immediately after the session, it will be checked peripheral blood flow through US surface in color Doppler mode.

Official Title
-----------------
Acute Effects on Oxygen Consumption and Blood Flow After a Single Session of Whole Body Vibration

Conditions
-----------------
Aged, Oxygen Consumption

Intervention / Treatment
-----------------
* Other: whole body vibration training in vibrating platform in young
* Other: whole body vibration training in vibrating platform in elderly


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy young adults (between 20 to 30 years) and healthy elderly (between 60 to 74 years), sedentary according International Physical Activity Questionnaire. Exclusion Criteria: presence of thrombosis, labyrinthitis, osteoporosis and individuals who have difficulty adapting to the assessment or training protocol.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Interventional Model Description: acute wbv session, measuring ergospirometric variables during protocol and blood pressure, borg exertion, borg dyspnoea, blood lactate, heart rate and SpO2 before and after protocol.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: healthy young and elderly<br>young adults (20 to 30 years) compare to elderly (60 to 74 years) | Other: whole body vibration training in vibrating platform in young<br> <br> * Other names: WBV;Other: whole body vibration training in vibrating platform in elderly<br> <br> * Other names: WBV;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VO2 through the gas exchange measured by Cortex Metamax | an atoxic mask measure oxygen consumption and carbon dioxide production in ml/kg/min-1, breathe by breathe | up to 06 months | 
| peripheral blood Lactate | a noninvasive evaluate using an Lactimeter | up to 06 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oxygen Consumption, Aged, Whole Body Vibration
Parathyroid Hyperplasia in Patients With Chronic Kidney Disease.

Study Overview
=================
Brief Summary
-----------------
Secondary hyperparathyroidism is an important complication in patient with chronic kidney disease . It is associated with bone complication and an increase in cardiovascular mortality The parathyroid hormone rises in these patients as consequence of low concentration of vitamin D3 ,reduction in quantities of serum calcium, phosphorus retention and reduction of vitamin D receptors sensitive to calcium.

Official Title
-----------------
Correlation of Parathyroid Hyperplasia by Ultrasound With Clinical and Laboratory Findings in Patients With Chronic Kidney Disease.

Conditions
-----------------
Chronic Kidney Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stage 5 chronic renal failure dialysis (peritoneal ,or hemodialysis) since 3---5 years Exclusion Criteria: previous of neck surgery. Patients refusal to participate in the study or voluntary withdrawal
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| chronic kidney diseases<br>patients with chronic renal failure on dialysis since 3-5 years | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of patients with high parathyroid hormone level | laboratory measurement of parathyroid hormone | 1 day |
ICI-combined Strategies Presented With Promising Efficacy in NSCLC Patients

Study Overview
=================
Brief Summary
-----------------
Due to insufficient data on immune checkpoint inhibitor (ICI)-combined strategies specialized for non-small cell lung cancer (NSCLC) patients with non-EGFR driver genes alterations. This retrospective study aimed to assess its efficacy in this subset of patients in the first and higher-line settings.

Official Title
-----------------
ICI-combined Strategies Presented With Promising Efficacy in NSCLC Patients With Non-EGFR Oncogenic Genetic Alterations

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: immune checkpoint inhibitor-combined


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18，Advanced Non-small Cell Lung Cancer Confirmed by Histopathology Patients with non-EGFR driver gene alterations Treatment with immunotherapy Exclusion Criteria: - Patients with two or more driver gene alterations Patients with contraindication of chemotherapy Pregnant or breast feeding women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: immune checkpoint inhibitor-combined|Pembrolizumab and Sintilimab|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Progression-free survival | January 2018 to January 2021 | 
| OS | Overall survival | January 2018 to January 2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patients non-EGFR oncogenic genetic alterations
Computer-Based Therapy for Mild Cognitive Impairment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the neuropsychological and neurophysiological impacts of a computer-based training program designed to improve the cognitive performance of patients with mild cognitive impairment (MCI).

Detailed Description
-----------------
The study is a randomized, double-blind, controlled trial of a computerized, cognitive intervention with three main goals: 1) to assess the magnitude of improvements in memory, language function, and cognitive function following computer training, 2) to investigate the neurophysiological mechanisms underlying such neuropsychological improvements, and 3) to demonstrate the feasibility of using this kind of computer-based therapy in older populations.

Official Title
-----------------
Computer-Based Therapy for Mild Cognitive Impairment

Conditions
-----------------
Mild Cognitive Impairment

Intervention / Treatment
-----------------
* Procedure: Computer-based training for Mild Cognitive Impairment (MCI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1)65 - 90 years of age 2)Meet definition for MCI including complaints of cognitive decline as indicated by patient report and/or informant report, and corroborated by clinician judgment and, the absence of dementia, defined as impairment of memory and at least one other domain of cognitive function. 3)Fluency in English 4)Willing to meet the time commitment of the study - Exclusion Criteria: Clinically significant cerebrovascular disease Individuals scheduled to begin acetylcholinesterase inhibitor (AChEI) therapy -

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Computer-based training for Mild Cognitive Impairment (MCI)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The study investigates changes in a neuropsychological assessment battery pre-randomization |  |  | 
| and upon the completion of training. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early evaluations will be conducted from brain imaging; specifically, date |  |  | 
| obtained via positron emission tomography (PET), magnetoencephalography (MEG), |  |  | 
| electroencephalography (EEG), and functional magnetic resonance imaging (fMRI) |  |  | 
| studies. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cognitive remediation, Cognitive impairment, computer, training
Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Study Overview
=================
Brief Summary
-----------------
The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.

Official Title
-----------------
Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Specimen sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants willing and able to provide written informed consent Participants are willing and able to provide appropriate photo identification Participant's age 18 - 100 years old Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.) Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records Exclusion Criteria: Participants who are pregnant or nursing Participants with a known history of HIV, hepatitis, or other infectious diseases Participants who have taken an investigational product in the last 30 days Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months Participants currently enrolled in a clinical trial Participants currently in remission

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Specimen sample|Participants will have up to 100 mL of whole blood collected.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biospecimen & Clinical Data Collection | The primary objective is to collect 2000 whole blood samples from subjects who are diagnosed with active lung cancer. The purpose of this study is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with various active lung cancers so that investigations can analyze how the immune response can take place, and aid in understanding active lung cancer biomarkers for future early diagnosis and treatment options. | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung cancer, NSCLC